Overview
There are nearly 300,000 patients with severe or intermediate thalassemia in China. Growth retardation is the most significant health issue for children and adolescents with transfusion-dependent thalassemia (TDT), placing a substantial economic burden on their families and a serious social strain on the labor force. Investigating the growth and development of these children and adolescents, and establishing targeted intervention plans, holds significant social value for public health practice.
- To screen and identify pediatric patients with growth problems by conducting growth and development assessments in high-incidence areas of China, including physical development, endocrine function, nutritional status, brain function and lifestyle behaviors.
- Implement the MENBS clinical interventions for pediatric patients with growth
problems, concentrating on the following areas:
- Monitor: Continuously monitor health-related indicators through regular follow-up.
- Education: Provide health education to improve the cognition of patients and their families.
- Nutrition: Assess patients' nutritional risks and develop personalized diet plans.
- Behavior: Recommend appropriate exercise plans to promote physical development.
- Support: Conduct home visits, offer free clinics and establish a support network.
- Repeat growth assessment for pediatric patients with growth problems after 1-year clinical interventions.
- Evaluate the effectiveness of MENBS interventions by comparing changes in growth and development indicators.
Eligibility
Inclusion Criteria:
- Subjects diagnosed with transfusion-dependent thalassemia (TDT)
- Male or female age ≤18 years
- Subjects who are willing and able to provide written informed consent
Exclusion Criteria:
- Not applicable